Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free BIAF Stock Alerts

bioAffinity Technologies (BIAF) Competitors

bioAffinity Technologies logo
$0.40 +0.02 (+4.99%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.41 +0.01 (+1.47%)
As of 08/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BIAF vs. IMRN, XCUR, AKTX, BIVI, and APRE

Should you buy bioAffinity Technologies stock or one of its competitors? bioAffinity Technologies's main competitors and comparable companies include Immuron (IMRN), Exicure (XCUR), Akari Therapeutics (AKTX), BioVie (BIVI), and Aprea Therapeutics (APRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does bioAffinity Technologies compare to Immuron?

Immuron (NASDAQ:IMRN) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, bioAffinity Technologies had 5 more articles in the media than Immuron. MarketBeat recorded 8 mentions for bioAffinity Technologies and 3 mentions for Immuron. Immuron's average media sentiment score of 0.96 beat bioAffinity Technologies' score of 0.36 indicating that Immuron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immuron has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.05, meaning that its stock price is 205% less volatile than the broader market.

Immuron has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. Immuron's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuronN/A N/A N/A
bioAffinity Technologies -257.30%-220.52%-136.76%

Immuron has higher earnings, but lower revenue than bioAffinity Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuron$4.72M1.88-$3.38MN/AN/A
bioAffinity Technologies$6.16M0.53-$14.91M-$7.30N/A

0.1% of Immuron shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Immuron beats bioAffinity Technologies on 8 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to Exicure?

bioAffinity Technologies (NASDAQ:BIAF) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

bioAffinity Technologies has a beta of -1.05, meaning that its share price is 205% less volatile than the broader market. Comparatively, Exicure has a beta of 3.65, meaning that its share price is 265% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Exicure
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, bioAffinity Technologies had 5 more articles in the media than Exicure. MarketBeat recorded 8 mentions for bioAffinity Technologies and 3 mentions for Exicure. Exicure's average media sentiment score of 1.96 beat bioAffinity Technologies' score of 0.36 indicating that Exicure is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Neutral
Exicure Very Positive

Exicure has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. Exicure's return on equity of -179.41% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-257.30% -220.52% -136.76%
Exicure N/A -179.41%-64.37%

Exicure has lower revenue, but higher earnings than bioAffinity Technologies. Exicure is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$6.16M0.53-$14.91M-$7.30N/A
Exicure$500K15.93-$4.95M-$1.32N/A

Summary

Exicure beats bioAffinity Technologies on 10 of the 12 factors compared between the two stocks.

How does bioAffinity Technologies compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

bioAffinity Technologies has higher revenue and earnings than Akari Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
bioAffinity Technologies$6.16M0.53-$14.91M-$7.30N/A

Akari Therapeutics currently has a consensus target price of $32.33, indicating a potential upside of 328.82%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Akari Therapeutics is more favorable than bioAffinity Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, bioAffinity Technologies had 5 more articles in the media than Akari Therapeutics. MarketBeat recorded 8 mentions for bioAffinity Technologies and 3 mentions for Akari Therapeutics. bioAffinity Technologies' average media sentiment score of 0.36 beat Akari Therapeutics' score of 0.30 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Akari Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.05, suggesting that its stock price is 205% less volatile than the broader market.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Akari Therapeutics has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. Akari Therapeutics' return on equity of -142.03% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -142.03% -73.04%
bioAffinity Technologies -257.30%-220.52%-136.76%

Summary

Akari Therapeutics beats bioAffinity Technologies on 9 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to BioVie?

BioVie (NASDAQ:BIVI) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

4.6% of BioVie shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioVie has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. BioVie's return on equity of -110.75% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
BioVieN/A -110.75% -99.07%
bioAffinity Technologies -257.30%-220.52%-136.76%

BioVie has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.05, suggesting that its stock price is 205% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioVie
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

bioAffinity Technologies has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/A-$17.54M-$3.15N/A
bioAffinity Technologies$6.16M0.53-$14.91M-$7.30N/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than BioVie. MarketBeat recorded 8 mentions for bioAffinity Technologies and 7 mentions for BioVie. bioAffinity Technologies' average media sentiment score of 0.36 beat BioVie's score of 0.12 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioVie
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BioVie beats bioAffinity Technologies on 6 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to Aprea Therapeutics?

bioAffinity Technologies (NASDAQ:BIAF) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aprea Therapeutics has lower revenue, but higher earnings than bioAffinity Technologies. Aprea Therapeutics is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$6.16M0.53-$14.91M-$7.30N/A
Aprea Therapeutics$290K29.52-$12.60M-$1.08N/A

Aprea Therapeutics has a consensus target price of $3.07, indicating a potential upside of 351.05%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than bioAffinity Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aprea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

bioAffinity Technologies has a net margin of -257.30% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-257.30% -220.52% -136.76%
Aprea Therapeutics -4,405.59%-47.60%-40.97%

bioAffinity Technologies has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

In the previous week, Aprea Therapeutics had 7 more articles in the media than bioAffinity Technologies. MarketBeat recorded 15 mentions for Aprea Therapeutics and 8 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 0.36 beat Aprea Therapeutics' score of 0.24 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Aprea Therapeutics beats bioAffinity Technologies on 12 of the 15 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIAF vs. The Competition

Export
MetricbioAffinity TechnologiesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.26M$3.71B$7.01B$13.07B
Dividend YieldN/A3.69%2.57%10.45%
P/E RatioN/A10.78271.2725.38
Price / Sales0.531,278.41588.9779.38
Price / CashN/A102.8870.4850.90
Price / Book0.8616.7812.926.25
Net Income-$14.91M-$13.32M$3.45B$347.82M
7 Day Performance-21.16%1.76%1.16%1.08%
1 Month Performance-44.34%1.14%1.37%0.82%
1 Year Performance-94.25%54.35%62.53%20.99%

bioAffinity Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIAF
bioAffinity Technologies
0.6044 of 5 stars		$0.40
+5.0%		N/A-94.7%$3.26M$6.16MN/A10
IMRN
Immuron
0.7785 of 5 stars		$1.10
flat		N/A-39.5%$8.88M$4.72MN/AN/A
XCUR
Exicure
1.2796 of 5 stars		$1.40
+2.2%		N/A-81.8%$8.73M$500KN/A50
AKTX
Akari Therapeutics
2.3661 of 5 stars		$7.73
+2.7%		$32.33
+318.3%		-81.0%$8.62MN/AN/A9
BIVI
BioVie
0.2885 of 5 stars		$1.27
+15.5%		N/A-15.7%$8.30MN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BIAF) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel